Changing the Law in California

Mary Sundsmo UC San Diego ADRC Ruth Mulnard UC Irvine ADRC The Law
The process of changing the law
The aftermath

The Law

AB 2328

 Consistent with the Common Rule (45 CFR §46) and other federal and state laws and regulations pertaining to human subject protection

- The law separates Emergency Room environment from Non-emergency Room environment (AD research)
- Criteria for use of a surrogate:
 - Research studies relating to cognitive impairment, lack of capacity, or serious or life-threatening diseases
 - Protocol specific.
 - Must be requested through the IRB.
 - IRB application must include a protocol specific plan for decision – making capacity assessment (DMC).
 - If subject expresses dissent or resistance, excluded from study.

Determining the Decision Making Capacity of the Subject

- Attempt to obtain informed consent from the subject.
- No gold standard

 Protocol specific plan for assessment should include understanding, expression of a reasoned choice, nature of research, consequences of participation, alternatives to participation (MacArthur Competency Tool, Dan Marson interpretation) Usually involves reiterating a simplified version of the consent and protocol specific questions.

Assessment of the DMC of the surrogate is only used when there is reason to believe surrogate has impaired DMC.

When the subject lacks DMC

 Inform the subject of the investigator's intent to use a surrogate

Document discussion in research file

Hierarchy of potential surrogates

- Person's agent named in an advance healthcare directive
- Conservator or guardian with authority to make health care decisions
- Spouse
- Domestic partner
- Adult son or daughter
- Custodial parent
- Adult brother or sister
- Adult grandchild
- Available adult relative with the closest degree of kinship

Disagreement

 No surrogate consent may be utilized if there is a disagreement whether to consent among members of the highest available priority class.

Responsibilities of the Investigator

The surrogate must:

- Have reasonable knowledge of the subject
- Be familiar with the subject's level of impairment
- Be willing to serve as substitute decision maker
- Understand the risks, potential benefits, procedures and alternatives to the research participation.
- Make decisions based on the subject's known preferences or surrogate's judgment of what subject's preference would be

Self Certification Form

Surrogate must be advised that if a higher-ranking surrogate is identified at anytime, defer to his/her decision regarding participation in research If potential surrogate identifies a person at a higher rank, the investigator is responsible to contact such individual to determine if they want to serve as surrogate

Reconsenting Subjects

Criteria which would normally trigger reconsenting a subject apply (SAEs, change in protocol)
 Change of surrogate
 Subject regains cognitive function

The Process

Did we have any idea of what we were getting ourselves into?

Not a clue!
First step: Educate ourselves

Our education

Talk to a local legislator to assess legislative interest.
We needed a sponsor.
Contact UCSD IRB to learn their interpretation of the current law.

In search of a sponsor

- Alzheimer's Association California Council Public Policy arm
 - Not interested at this time
- UC Office of the President (UCOP) moving a mountain
- UCOP agrees to sponsor legislation 5 months after initial contact (Late summer 2001)
 Alzheimer's Association with a nudge from national gives us their support

Finding support in the research community

California AD researchers contacted through 10 state ARCC's. Ethics committee formed Informational meeting with experts: Jason Karlawish and Dan Marson Outcome: Guarded support, fear of bringing attention to a major problem!

Time to spread the net

Researchers in other areas of cognitive impairment contacted

Stroke, Parkinson's disease, MS, Huntington's disease, head trauma, and HIV.

Sample letters of support sent out

ARCC's formed the backbone of the process

Support from family service groups and affected individuals

Alzheimer's Association
Family Caregiver Alliance
Support groups contacted
Sample letters sent out

Identification of potential opposition

Mental health groups
 Civil rights groups
 After the bill was introduced, they came forward.

Legislative Timeline-The Assembly

• UCOP drafts language of the bill AB 2328 introduced to the CA Assembly – February 21, 2002 by San Diego Assemblyman Howard Wayne Assigned to two committees: Health and Judiciary-Hearings in April and May Amendments taken The floor of the Assembly-May

The Senate

Assigned to two committees: Health and Human Services & Judiciary Health and Human Services – June Amendments taken Judiciary chair decided not to hear bill Floor of the Senate Floor of the Assembly

The final weeks

The Bill is chaptered
Sent to the Governor
Signed September 11, 2002
Bill would become law January 1, 2003

In the interim

 UCLA halts research involving human subjects who cannot consent for themselves

UCSF is reprimanded for inappropriate consenting processes
UC Davis VA halts human subject research
March 2002 – Newsweek has on its cover – 'a human crouching in a cage'

The Aftermath

Implementation of the Law

Committee formed to draft the Guidelines
Finalized and sent to all UC IRBs
Local policy formulated specific to each campus

Issues which have arisen

Site issues

 UCSF: IRB wants outside MDs to determine capacity to consent

 Stanford VA: wants 2 VA MDs, not involved in the protocol, to determine capacity

Issues (continued)

Opposition

- Major opponent: new bill introduced AB 1371
 Feb 2003
- Attempts to change many features of our bill, including requiring primary care MD to determine capacity
- UCOP legislative analysts meet with sponsor of AB 1371 to draft amendments

What we learned

- We were lucky
- The most unlikely issues will be raised as points of discussion
- It is possible to change the law! The process really does work!

The future

Impact of the legislation is still being felt
Presentation at GSA in November
Manuscript describing the process, pitfalls, etc.

Acknowledgements

Ruth Mulnard, UC Irvine Leon Thal, MD – UCSD Bill Jagust, MD – UC Davis Dan Marson, PhD, JD - U Alabama Jason Karlawish, MD - Penn Mary Beth Stamps, UC Davis Jean Coleman, UC Davis Karen Metz, UCLA